Legend Biotech Corporation

NasdaqGS:LEGN Stock Report

Market Cap: US$4.0b

Legend Biotech Future Growth

Future criteria checks 6/6

Legend Biotech is forecast to grow earnings and revenue by 51.6% and 23.1% per annum respectively. EPS is expected to grow by 56.3% per annum. Return on equity is forecast to be 29% in 3 years.

Key information

51.6%

Earnings growth rate

56.32%

EPS growth rate

Biotechs earnings growth23.2%
Revenue growth rate23.1%
Future return on equity29.04%
Analyst coverage

Good

Last updated17 Dec 2025

Recent future growth updates

Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 15
Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Recent updates

Investors Don't See Light At End Of Legend Biotech Corporation's (NASDAQ:LEGN) Tunnel And Push Stock Down 26%

Dec 11
Investors Don't See Light At End Of Legend Biotech Corporation's (NASDAQ:LEGN) Tunnel And Push Stock Down 26%

Legend Biotech: Is Carvykti Changing Cancer Treatment Forever?

Nov 25

Here's Why Legend Biotech (NASDAQ:LEGN) Can Manage Its Debt Despite Losing Money

Aug 04
Here's Why Legend Biotech (NASDAQ:LEGN) Can Manage Its Debt Despite Losing Money

There's Reason For Concern Over Legend Biotech Corporation's (NASDAQ:LEGN) Massive 32% Price Jump

Jun 14
There's Reason For Concern Over Legend Biotech Corporation's (NASDAQ:LEGN) Massive 32% Price Jump
User avatar

Expanding Facilities In Belgium And New Jersey Will Boost Reach

Expanded manufacturing and outpatient approval are set to increase supply and streamline distribution, potentially boosting net margins and revenue.

Legend Biotech's Carvykti Is Taking Off, And It's Still Early (Rating Upgrade)

Mar 11

Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4)

Jan 07

Some Legend Biotech Corporation (NASDAQ:LEGN) Shareholders Look For Exit As Shares Take 26% Pounding

Jan 02
Some Legend Biotech Corporation (NASDAQ:LEGN) Shareholders Look For Exit As Shares Take 26% Pounding

Legend Biotech: The Story Brightens

Dec 05

Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 15
Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion

Sep 18

Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking

Aug 01
Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking

Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges

Jul 30

Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt

Jul 05
Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt

Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

May 14

Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

May 13
Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)

Mar 15

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Mar 06
Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Legend Biotech: Solid Traction With Carvykti Rollout

Jan 29

Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up

Jan 16
Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Nov 09
Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Apr 12
Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Dec 14
An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Legend Biotech wins approval of Carvykti for multiple myeloma in Japan

Sep 27

Legend Biotech stock slides on proposed ADS offering

Jul 25

Legend Biotech ends Phase 1 trial for lymphoma candidate

Jul 07

Earnings and Revenue Growth Forecasts

NasdaqGS:LEGN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20282,5447618668766
12/31/20272,0504336025519
12/31/20261,54011422621014
12/31/20251,035-259-122-20314
9/30/2025909-240-189-170N/A
6/30/2025797-325-290-275N/A
3/31/2025728-218-273-263N/A
12/31/2024627-177-158-144N/A
9/30/2024520-348-176-158N/A
6/30/2024456-285-165-143N/A
3/31/2024343-466-264-239N/A
12/31/2023285-518-416-393N/A
9/30/2023233-509-371-347N/A
6/30/2023165-532-378-359N/A
3/31/2023112-517-276-262N/A
12/31/2022117-446-224-201N/A
9/30/2022106-416-237-221N/A
6/30/202296-457-221-194N/A
3/31/2022119-346-293-250N/A
12/31/202169-404-244-198N/A
9/30/202193-356-245-185N/A
6/30/202189-297-259-205N/A
3/31/202180-340-256-204N/A
12/31/202075-266-253-223N/A
9/30/202059-310-300-227N/A
6/30/202064-271-209-143N/A
3/31/202061-165-160-125N/A
1/1/202062-102-110-83N/A
12/31/201849-3N/A308N/A
12/31/2017249N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LEGN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.3%).

Earnings vs Market: LEGN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: LEGN is expected to become profitable in the next 3 years.

Revenue vs Market: LEGN's revenue (23.1% per year) is forecast to grow faster than the US market (10.5% per year).

High Growth Revenue: LEGN's revenue (23.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: LEGN's Return on Equity is forecast to be high in 3 years time (29%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/31 21:51
End of Day Share Price 2025/12/30 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Legend Biotech Corporation is covered by 30 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Suranjit MukherjeeBTIG
Justin ZelinBTIG